FDA Warns Drug Manufacturers to Stop Marketing Unapproved Versions of Oxycodone
July 6, 2012
In the United States, companies that produce drugs and medications are required to have approval of their products from the Food and Drug Administration (FDA), before they can go onto the mass market; however, hundreds of thousands of pounds of unapproved versions of different medications are made and sold in the United States each year.
The FDA is battling this growing problem of drug injuries by unapproved product according to a press release yesterday that serves as an immediate cease and desist warning to all companies involved in the manufacture and marketing of unapproved versions of the narcotic painkiller Oxycodone.
Ilisa Bernstein, acting director of the Office of Compliance in the FDA’s Center for Drug Evaluation and Research, stated that the campaign was being conducted in order to keep patients distanced from medications that may be “unsafe, ineffective, and of poor quality.”
The statement went on to read that all companies producing unapproved narcotics have 45 days to stop manufacturing and 90 days to halt the shipment of narcotics put on the market before September 19th, 2011. Products that must abide by this timeframe must also have to have been listed in the FDA’s Drug Registration and Listing System, and have been commercially used and sold prior to today.Back to the Blog